Compare Constellation Energy Corporation (CEG) vs GSK plc (GSK) Price & Performance

Constellation Energy (CEG) trades at $279.75, up 3.45% in the past 24 hours, with a bullish technical signal and strong support near $277. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and new contracts like the Walmart PPA. Revenue growth is robust, with 2026 projections at $31.3 billion, and profitability metrics show a net margin of 11.08% and ROE of 15.26%.

The outlook is positive, with a consensus price target of $332.13 implying 19% upside, supported by AI-driven electricity demand and nuclear fleet advantages. Risks include execution challenges in integrating acquisitions and potential regulatory shifts. Analysts are bullish, with 70% buy ratings, citing long-term growth from data center power needs.

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.